ACRX Share Price

Open 3.70 Change Price %
High 3.70 1 Day -0.25 -6.76
Low 3.40 1 Week 0.30 9.52
Close 3.45 1 Month 1.35 64.29
Volume 1059092 1 Year 0.37 12.01
52 Week High 4.08
52 Week Low 1.95
ACRX Important Levels
Resistance 2 3.73
Resistance 1 3.61
Pivot 3.52
Support 1 3.29
Support 2 3.17
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
QQQ 143.96 -0.63%
SIRI 5.83 8.16%
FB 170.44 2.92%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SHOR 7.50 28.21%
OPNT 14.53 27.46%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
LPSN 13.50 18.42%
TREE 217.15 18.14%
AXTI 8.80 15.79%
DRYS 1.20 15.38%
More..
NASDAQ USA Top Losers Stocks
EDMC 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
IPCI 1.36 -45.38%
DVOX 0.05 -44.44%
GLCH 0.70 -44.00%
More..

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)

ACRX Technical Analysis 4
As on 27th Jul 2017 ACRX Share Price closed @ 3.45 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.91 & Strong Buy for SHORT-TERM with Stoploss of 2.53 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACRX Target for July
1st Target up-side 2.56
2nd Target up-side 2.85
3rd Target up-side 3.13
1st Target down-side 1.74
2nd Target down-side 1.45
3rd Target down-side 1.17
ACRX Other Details
Segment EQ
Market Capital 65612500.00
Sector Healthcare
Industry Medical Appliances & Equipment
Offical website http://www.acelrx.com
ACRX Address
ACRX
351 Galveston Drive
Redwood City, CA 94063
United States
Phone: 650-216-3500
Fax: 650-216-6500
ACRX Latest News
Interactive Technical Analysis Chart AcelRx Pharmaceuticals, Inc. ( ACRX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on AcelRx Pharmaceuticals, Inc.
ACRX Business Profile
AcelRx Pharmaceuticals, Inc., incorporated on July 13, 2005, is a development-stage company. It is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The Company has completed Phase 2 clinical development for two additional product candidates, the Sufentanil NanoTab BTP Management System, or ARX-02, for the treatment of cancer breakthrough pain (BTP), and the Sufentanil/Triazolam NanoTab, or ARX-03, designed to provide mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office. The Company is preparing to initiate two Phase 3 clinical trials for its product candidate, the Sufentanil NanoTab PCA System, or ARX-01. Its operations are based in Redwood City, California.